METTL3 and metabolic dysfunction-associated steatotic liver disease: We deciphered the mechanism of action of METTL3, involving m6A-modification of SREBP cleavage-activating protein (SCAP), which promotes cholesterol biosynthesis, subsequently impairing cytotoxic CD8+ T cells in NAFLD-HCC.